{
    "nctId": "NCT02238808",
    "briefTitle": "A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers",
    "officialTitle": "PRe-operative ESTradiOl Window of Opportunity Study in Post-Menopausal Women With Newly Diagnosed ER Positive Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Estrogen Receptor Positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 19,
    "primaryOutcomeMeasure": "To assess changes in breast cancer proliferation after a 7-14 day trial of estradiol in newly diagnosed estrogen receptor positive post-menopausal breast cancer patients prior to surgery.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female gender\n* Estrogen receptor positive (ER+) breast cancer\n* HER2 negative breast cancer\n* Post-menopausal by greater than 5 years\n* No previous hormonal replacement therapy\n* Low to intermediate histologic grade\n* ECOG Performance status of 0 of 1\n* Adequate hematological, renal and hepatic function is required\n* Ability to take oral medication\n* Patient must have adequate tissue for diagnosis, biomarkers and Ki67 assays\n\nExclusion Criteria:\n\n* Pre-menopausal women\n* Locally advanced or metastatic breast cancer\n* Current, previous or planning for pre-operative treatment with chemotherapy, hormone therapy including corticosteroids, radiation therapy for malignancy or other condition\n* Known hypersensitivity or intolerance to estradiol\n* Ischemic changes on baseline electrocardiogram\n* Symptomatic but untreated cholelithiasis\n* History of deep vein thrombosis, pulmonary embolism, stroke, acute myocardial infarction, congestive cardiac failure, untreated hypertension or known inherited hypercoagulable disorder\n* Undiagnosed abnormal vaginal bleeding or prior history of endometrial cancer\n* Untreated metabolic disturbances (glucose \\> 15.0 mmol/L and triglycerides \\> 400 mg/dL)\n* Current treatment with drugs known to be moderate or strong inhibitors of inducers of isoenzyme CYP3A4\n* The time between study enrolment and definitive breast surgery is not sufficient for administration of at least 7 days of estradiol",
    "sex": "FEMALE",
    "minimumAge": "55 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}